{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:57:42Z","timestamp":1764071862020,"version":"3.45.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"DOI":"10.7759\/cureus.97733","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:53:21Z","timestamp":1764071601000},"source":"Crossref","is-referenced-by-count":0,"title":["New-Onset Guttate Psoriasis Induced by Durvalumab: Potential Role of Bisoprolol"],"prefix":"10.7759","author":[{"given":"Olivia","family":"Tshika Wa Kabeya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieu-Donn\u00e9","family":"Kaziga Wiyaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibtissam","family":"Moustaghfir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1051\/medsci\/2019225","article-title":"[The revolution of immuno-oncology therapy: review of immune checkpoint inhibitors efficacy]","volume":"35","author":"Dubois M","year":"2019","unstructured":"Dubois M, Ardin C, Andr\u00e9 F, Scherpereel A, Mortier L. [The revolution of immuno-oncology therapy: review of immune checkpoint inhibitors efficacy]. Med Sci (Paris). 2019, 35:937-45. 10.1051\/medsci\/2019225","journal-title":"Med Sci (Paris)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmra.2021.11.550","article-title":"[Real-world study of durvalumab use as consolidation therapy after chemoradiotherapy in unresectable stage III NSCLC: the French PACIFIC-R cohort]","volume":"14","author":"Chouaid C","year":"2022","unstructured":"Chouaid C, Pichon E, Wislez M, et al.. [Real-world study of durvalumab use as consolidation therapy after chemoradiotherapy in unresectable stage III NSCLC: the French PACIFIC-R cohort]. Rev Mal Respir Actual. 2022, 14:60-1. 10.1016\/j.rmra.2021.11.550","journal-title":"Rev Mal Respir Actual"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2018.07.005","article-title":"[Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment]","volume":"105","author":"Passat T","year":"2018","unstructured":"Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C, Bennouna J. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment]. Bull Cancer. 2018, 105:1033-41. 10.1016\/j.bulcan.2018.07.005","journal-title":"Bull Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2019.09.005","article-title":"[Immune-related adverse events after immune checkpoints inhibitors in 2019: an update]","volume":"41","author":"Comont T","year":"2020","unstructured":"Comont T, Belliere J, Sibaud V, et al.. [Immune-related adverse events after immune checkpoints inhibitors in 2019: an update]. Rev Med Interne. 2020, 41:37-45. 10.1016\/j.revmed.2019.09.005","journal-title":"Rev Med Interne"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2018.01.047","article-title":"[Dermatologic toxicities of immune checkpoint inhibitors]","volume":"145","author":"Sibaud V","year":"2018","unstructured":"Sibaud V, Boulinguez S, Pag\u00e8s C, et al.. [Dermatologic toxicities of immune checkpoint inhibitors]. Ann Dermatol Venereol. 2018, 145:313-30. 10.1016\/j.annder.2018.01.047","journal-title":"Ann Dermatol Venereol"},{"key":"ref6","article-title":"Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance","volume":"3","author":"Kim GK","year":"2010","unstructured":"Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010, 3:32-8.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48453","article-title":"New-onset psoriasis induced by durvalumab","volume":"15","author":"Shoukfeh R","year":"2023","unstructured":"Shoukfeh R, Yassine R, Turk D, Moossavi M, Nofzinger A. New-onset psoriasis induced by durvalumab. Cureus. 2023, 15:e48453. 10.7759\/cureus.48453","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15371","article-title":"Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment","volume":"47","author":"Lin WH","year":"2020","unstructured":"Lin WH, Lee KY, Lee WR, Shih YH. Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment. J Dermatol. 2020, 47:1041-5. 10.1111\/1346-8138.15371","journal-title":"J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081433","article-title":"Exacerbation of psoriasis with \u03b2-blocker therapy","volume":"181","author":"Waqar S","year":"2009","unstructured":"Waqar S, Sarkar PK. Exacerbation of psoriasis with \u03b2-blocker therapy. CMAJ. 2009, 181:60. 10.1503\/cmaj.081433","journal-title":"CMAJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2024.02.012","article-title":"Immune checkpoint inhibitor-induced psoriasis: diagnosis, management, and a review of cases","volume":"42","author":"Pach JJ","year":"2024","unstructured":"Pach JJ, Mbonu N, Bhullar S, Cohen JM, Leventhal JS. Immune checkpoint inhibitor-induced psoriasis: diagnosis, management, and a review of cases. Dermatol Clin. 2024, 42:481-93. 10.1016\/j.det.2024.02.012","journal-title":"Dermatol Clin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llac095","article-title":"Checkpoint inhibitor therapy and psoriasis: a\u00a0case series","volume":"48","author":"Hussain K","year":"2023","unstructured":"Hussain K, Kanji A, Zaheri S, et al.. Checkpoint inhibitor therapy and psoriasis: a\u00a0case series. Clin Exp Dermatol. 2023, 48:254-6. 10.1093\/ced\/llac095","journal-title":"Clin Exp Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-025-01554-3","article-title":"Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis","volume":"43","author":"Xiao J","year":"2025","unstructured":"Xiao J, Xia Z, Wu Z, Fang M. Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis. Invest New Drugs. 2025, 43:719-27. 10.1007\/s10637-025-01554-3","journal-title":"Invest New Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15330","article-title":"Psoriasis risk after beta-blocker exposure: description of a pharmacovigilance signal","volume":"88","author":"Azzouz B","year":"2022","unstructured":"Azzouz B, De Guizelin A, Lambert A, Fresse A, Morel A, Trenque T. Psoriasis risk after beta-blocker exposure: description of a pharmacovigilance signal. Br J Clin Pharmacol. 2022, 88:3813-8. 10.1111\/bcp.15330","journal-title":"Br J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/435952-new-onset-guttate-psoriasis-induced-by-durvalumab-potential-role-of-bisoprolol","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:53:22Z","timestamp":1764071602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/435952-new-onset-guttate-psoriasis-induced-by-durvalumab-potential-role-of-bisoprolol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.97733","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}